Discovery of New Transmitter Systems and Hence New Drug Targets.
| Autor: | Schwasinger-Schmidt T; Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, KS, USA. tschwasinger-schmidt@kumc.edu., Preskorn SH; Department of Psychiatry and Behavioral Science, University of Kansas School of Medicine-Wichita, Wichita, KS, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Advances in neurobiology [Adv Neurobiol] 2023; Vol. 30, pp. 181-193. |
| DOI: | 10.1007/978-3-031-21054-9_7 |
| Abstrakt: | The development of medications used to treat psychiatric conditions has largely proceeded through serendipity, where a potential drug to treat mental illness is identified by chance. This approach is based on a limited understanding of the underlying pathophysiology of mental illness and brain disorders. Identification of novel neurotransmitter systems has allowed for new molecular-based approaches for drug development that identify specific receptor targets to treat a specific symptom. An example of this approach includes the development of suvorexant, which is a dual orexin receptor antagonist FDA approved in 2014 for the treatment of insomnia. This chapter will discuss challenges in psychiatric drug development; the importance of identifying discrete neurotransmitter systems that target a specific symptom, not a syndrome; the orexin pathway and targets within this pathway that can be used to modulate sleep; and a high-throughput approach to streamlining drug development. (© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|